Cargando…

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis

Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq-NSCLC). Therefore, we aimed to indirectly compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mingye, Shao, Taihang, Ren, Yinan, Zhou, Caicun, Tang, Wenxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558711/ https://www.ncbi.nlm.nih.gov/pubmed/36249794 http://dx.doi.org/10.3389/fphar.2022.910656

Ejemplares similares

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
por: Chen, Xi, et al.
Publicado: (2023)

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
por: Liu, Shixian, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials
por: Gu, Lihu, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

PD-1 Inhibitors in the Advanced Esophageal Cancer
por: Hong, Ye, et al.
Publicado: (2019)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study
por: Lai, Sicen, et al.
Publicado: (2023)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
por: Shao, Taihang, et al.
Publicado: (2023)

Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
por: Liang, Leyi, et al.
Publicado: (2023)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
por: Lin, Shen, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
por: Kaiho, Taisuke, et al.
Publicado: (2023)

Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
por: Leete, Jessica C., et al.
Publicado: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_483ugj3jbnsn39k7j88sdsf3l3